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The suppression of immune responses in malignant gliomas is thought to be involved in glioma patho-
genesis. The newly identified tumor-secreted soluble decoy receptor 3 (DcR3) can bind to the ligands CD95L
and LIGHT, thereby neutralizing their pro-apoptotic actions. Little is known of the production of DcR3
by glioma cells. This study investigated the serum concentration of DcR3 in glioma patients before and
after tumor removal. Blood samples were taken from 17 glioma patients and 10 control patients. The serum
DcR3 concentration was measured using a DcR3 enzyme-linked immunosorbent assay. There was no
statistically significant difference between preoperative (0.069 ( 0.027 ng/mL) and postoperative DcR3
concentrations (0.068 ( 0.022 ng/mL; p = 0.951). Similarly, there was no difference in preoperative DcR3
concentration between glioma patients (0.069 (  0.027 ng/mL) and controls (0.063 (  0.023 ng/mL; p =
0.106). Our study demonstrated no alteration in DcR3 concentration in glioma patients before and after
tumor removal.
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Systemic and local immune responses are suppressed in
malignant gliomas, and this suppression has been attributed
a role in the pathogenesis of glioma. Soluble immunosup-
pressive cytokines are implicated as a cause of anergy in
immune effector cells. The CD95 system may be involved in
immune-modulating processes that could promote glio-
ma cell proliferation in vivo. Down-regulation of CD95
expression at the cell surface, shedding of soluble CD95,
and inhibition of the intracellular death-signaling pathway
are mechanisms that may enable glioma cells to escape a
CD95-mediated immune response [1].
Recently, a soluble decoy receptor for CD95L, decoy
receptor 3 (DcR3), has been identified [2–4]. DcR3 binds
to the ligands CD95L and LIGHT, thereby neutralizing
their pro-apoptotic actions [2,4]. DcR3 is frequently over-
expressed by malignant tumors arising from the lung or
gastrointestinal tract [2,3], and is amplified in colon and
lung cancers [2]. Roth et al also demonstrated that DcR3 is
expressed by malignant gliomas and suppresses CD95
ligand-induced apoptosis and chemotaxis [1]. In their
studies, DcR3 expression was localized mainly in glioma
cells in areas surrounding large ischemic necrosis. Wu et al
demonstrated that the serum DcR3 concentration was
increased in 82 of 146 patients with malignant tumors [5].
However, there are no reports about whether DcR3 can be
detected in serum or whether the serum DcR3 concentration
changes after surgical removal of malignant gliomas. In this
study, we examined the serum concentration of DcR3 in
glioma patients before and after surgery.
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MATERIALS AND METHODS
From 1999 to 2003, 17 patients were included in this study,
13 with astrocytomas and four with oligodendrogliomas.
Tumors were totally removed in 11 patients (8 astrocytomas,
3 oligodendrogliomas). Blood samples (10 mL) were taken
from glioma patients before and 8 days after tumor removal.
Patients with hypertensive intracerebral hemorrhage were
used as a control group. After formation of a clot, serum was
carefully collected and centrifuged at 3,000 rpm (EBA 3S
centrifuge; Hettich, Tuttlingen, Germany) for 5 minutes.
The supernatant was carefully aspirated and stored at
–30$C until analysis.
Serum DcR3 concentration was measured using the
Anawrahta human DcR3 enzyme-linked immunosorbent as-
say (ELISA) kit (Anawrahta Biotechnology, Taipei, Taiwan).
This employs the quantitative sandwich enzyme immuno-
assay technique. A monoclonal antibody specific for DcR3
was precoated onto a microplate before standards and sam-
ples were pipetted into the wells; the immobilized antibody
bound to any DcR3 present. After washing away any unbound
substances, a biotin-conjugated monoclonal antibody specific
for DcR3 was added to the wells. Following a wash to remove
any unbound biotinylated antibody reagent, streptavidin-
horseradish peroxidase was added to the wells. Any unbound
reagent was removed by washing, and a substrate solution
was added to develop color in proportion to the amount of
DcR3 bound in the initial step. Color intensity was measured
at 450 nm absorbance. Mean values and standard errors of the
mean were calculated. Data were analyzed using Student’s
t test, and p values of 0.05 or less were considered significant.
RESULTS
Serum concentrations of DcR3 in both glioma patients and
controls are shown in the Figure. The assay range was 0–
243 ng/mL. The preoperative DcR3 concentration in glioma
patients was 0.069 ( 0.027 ng/mL, which was not statisti-
cally significantly different from that in controls (0.063 (
0.023 ng/mL; p = 0.106). The postoperative DcR3 concentration
(0.068 ( 0.022 ng/mL) was not statistically different from the
preoperative concentration (0.069 ( 0.027 ng/mL; p = 0.951).
DISCUSSION
The newly identified tumor-secreted DcR3 neutralizes the
biologic effects of CD95L [2]. DcR3 has been attributed an
oncogenic role because it is preferentially produced by ma-
lignant tumor cells and, thus, might counteract CD95L-
mediated immune responses. By a similar mechanism, DcR3
may contribute to immune escape from tumors by binding to
the ligand LIGHT, which is highly expressed by activated T
cells and induces apoptosis in tumor cells [4]. Roth et al
demonstrated that human malignant gliomas express DcR3 in
vivo, that enhanced expression of DcR3 suppresses CD95L-
induced apoptosis in vitro, and that DcR3-expressing glioma
xenografts are less prone to immune cell infiltration than non-
DcR3-expressing glioma xenografts [1]. Conceivably, DcR3
secreted by tumors might protect them against apoptosis and,
consequently, tumors secreting DcR3 would gain a survival
advantage. Wu et al demonstrated that serum DcR3 should be
considered as a novel parameter for the diagnosis, treatment,
and prognosis of malignancies [5]. In their studies, 47 of 48
healthy individuals and patients with acute infection were
serum DcR3-negative. In contrast, 82 of 146 tumor patients
were serum DcR3-positive. Almost all serum DcR3-positive
individuals (82 of 83 cases) had malignancy, excluding one
case of liver cirrhosis.
In the study of Roth et al, DcR3 was detected in the
supernatants of most glioma cell samples in vitro [1]. There
are no reports in the literature of serum DcR3 concentrations
in patients with brain tumors. Our study showed detectable
serum concentrations of DcR3 in glioma patients. The pre-
operative serum concentration of DcR3 in glioma patients
was not significantly different from that in control patients.
Furthermore, the preoperative serum DcR3 concentration
Figure. Serum concentrations of decoy receptor 3 (DcR3) in both glioma
patients and controls.
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in glioma patients was not significantly different from the
postoperative concentration. However, the serum DcR3 con-
centration in glioma patients was very low. Wroblewski
et al demonstrated that DcR3 was degraded rapidly to a
major circulating metabolic fragment after subcutaneous
administration in primates and mice [6]. Although the
metabolism of DcR3 in brain tissue is unknown, our data
suggest that DcR3 is rapidly degraded. Another explanation
may be that the blood–brain barrier influences the trans-
fer of DcR3 from brain tissue to the systemic circulation.
DcR3 expression is localized mainly in glioma cells in ar-
eas surrounding large ischemic necrosis [1]. Interestingly,
this expression pattern is similar to that of CD95 [7,8], sug-
gesting the co-regulation of CD95 and DcR3 expression.
DcR3 up-regulation may reflect a protective mechanism
from CD95-mediated cell death. However, the relationship
between the expression of DcR3 in tumor cells and serum
DcR3 concentrations needs further investigation.
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